Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Golvatinib
- Development stage
- Phase 2
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Golvatinib is an investigational small molecule receptor tyrosine kinase inhibitor. It primarily targets the MET (hepatocyte growth factor receptor) and VEGFR2 (vascular endothelial growth factor receptor 2) pathways, both of which are implicated in tumor angiogenesis and cancer cell proliferation. Golvatinib was developed for the treatment of various solid tumors, including gastric cancer and head and neck squamous cell carcinoma. The drug was originally developed by Eisai.
- Brand names
- golvatinib
- Other names
- E7050E-7050E 7050golvatinib
02
Targets
EPH (EPH receptor family)MET (Mesenchymal-epithelial transition factor receptor)MST1R (Recepteur d'origine nantais)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on Golvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Golvatinib.